AbCellera Biologics Inc.
corporate_fare Company Profile
AbCellera Biologics Inc. (NASDAQ:ABCL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ABCL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ABCL spans 8-K, 424B5, 10-Q.
Recent high-impact activity:
- AbCellera Q3: Loss Narrows to $40.8M, $890M Liquidity After $200M Raise
- AbCellera Narrows Q3 Loss to $40.8M as ABCL635 Phase 2 Data Drives $200M Raise
- AbCellera Prices $200M Oversubscribed Offering at $9.75/Share
- AbCellera Prices Oversubscribed $200M Offering at $9.75, Above Recent Lows
- AbCellera Launches $200M Stock Offering on Heels of ABCL635 Phase 2 Win
Financial Snapshot
Short Interest & Short Volume
8.49 days to coverFINRA reported short interest of 29,023,512 shares in ABCL as of the October 30, 2026 settlement, a 6.2% decrease from the prior period — about 8.5 days to cover at its recent average daily volume. On November 19, 2026, 38.5% of ABCL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ABCL, detected from its recent SEC filings · based on capital-structure filings through 2026-08-11.
$200M Equity Offering Launched · Proceeds to Fund ABCL635 Advancement
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →